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Phase I/IIPurpose: This phase I/II study sought to determine the safety and maximum tolerated dose (MTD) of the
combination of rapamycin, an mTOR inhibitor, with short-course radiotherapy in rectal cancer patients.
Antitumor activity, changes in metabolic activity and perfusion on imaging, and changes in phosphory-
lation status of the mTOR pathway were also assessed.
Materials and methods: Patients with primary resectable rectal cancer were treated with short-course
hypofractionated radiotherapy (5  5 Gy) combined with oral rapamycin 1 week before and during radio-
therapy, followed by surgical resection.
Results: Thirteen patients were entered in phase I. One patient developed a dose-limiting toxicity, con-
sisting of a grade 4 leak and grade 4 bleeding. Because of an unexpected high rate of grade 3 postoper-
ative toxicity, it was decided to treat patients with delayed surgery in phase II. Primary endpoint for
phase II was tumor blood ﬂow (Ktrans) assessed by perfusion CT. Thirty-one patients were treated with
the MTD of 6 mg rapamycin daily. One patient (3%) developed a pathological complete response (pCR)
and 3 patients (10%) had a ypT1N0 tumor at the time of resection. No change in tumor perfusion was
observed on perfusion CT, but a signiﬁcant decrease of metabolic activity was found on PET-scan.
Conclusions: The combination of short-course radiotherapy and rapamycin turned out to be feasible, pro-
vided that the interval between neo-adjuvant treatment and surgical resection is at least 6 weeks.
Although from this cohort no clear increase in pCR could be observed, a clear metabolic response after
rapamycin run-in was observed, indicating a biological activity of this drug in rectal cancer.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 116 (2015) 214–220
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Pre-operative radiotherapy has an important role in the
treatment of rectal cancer. For primary resectable rectal cancer,
short-course hypofractionated radiotherapy (5  5 Gy) results in
a 50% reduction of local recurrence [1]. In view of the relatively
limited toxicity observed with this treatment, there is room for
treatment intensiﬁcation. In order to further increase tumor
response rates, radiotherapy can be combined with radiosensi-
tizing drugs. The mammalian target of rapamycin (mTOR) path-
way is attractive to exploit, because it plays a central role in
survival strategies of tumor cells and inﬂuences angiogenesis
[2]. Furthermore, it has been shown that mTOR has a direct linkwith the phosphatidylinositol-30-kinase (PI3K)/PTEN-AKT sur-
vival pathway [3]. Preclinical evidence shows a radiosensitizing
effect of mTOR inhibitors [4,5]. Especially the link between
mTOR inhibition and the inhibition of angiogenesis may be
important for the radiosensitizing effects [6]. Neovasculature
in tumors tends to be unstructured and leaky, leading to an
inefﬁcient blood ﬂow and hypoxic areas. Anti-angiogenic treat-
ments may result in normalization of this vasculature resulting
in improved oxygen supply [7]. If resection takes place within a
week after the completion of radiotherapy, no downsizing of
the tumor will occur. However, after an interval of at least
6 weeks, substantial downsizing can be observed [8,9]. As this
short course schedule is primarily used for relatively small
tumors, a small proportion of the patients will develop a
complete response. This opens the way for alternative organ
preservation treatment strategies [10].
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an immune suppressant. It was shown more than 20 years ago that
rapamycin also had antiproliferative effects in tumor cell lines.
During the last years analogs of rapamycin have been developed
as anti-cancer drugs. The advantage of rapamycin is that there is
extensive clinical experience with its use as immune suppressant
after kidney transplantation and it is an oral drug.
The objective of this trial was to investigate the safety and the
activity of rapamycin, administered before and during preopera-
tive radiotherapy in patients with resectable rectal cancer. The
purpose of phase I was to determine the recommended phase II
dose (RP2D). For phase II of this study, change in tumor perfusion
was chosen as the primary endpoint. We believe this is an attrac-
tive surrogate endpoint predicting response, as it can be measured
early after the start of treatment. Furthermore it gives insights into
the mechanism of action of rapamycin in rectal cancer with and
without radiation. It was hypothesized that rapamycin would lead
to a decrease of the activation status of mTOR related and depen-
dent molecules in the tumor reﬂected by a decrease in staining
for phosphorylated mTOR (p-mTOR) and phosphorylated
4E-BP1in tumor biopsies. 4E-BP1 is a protein that is activated
and dissociated from eIF4E after phosphorylation, leading to
increased translation, and is a downstream effector of mTOR
complex 1 (mTORC1).Fig. 1. Study outline for phase I (upperMaterials and methods
This was an open-label, single-institution prospective phase I/II
trial, approved by the local Medical Ethical Committee.
Radiotherapy was performed at Maastro Clinic, surgery was done
in the referring hospital. All patients gave written informed con-
sent. The trial has been registered at clinicaltrials.cov
(NCT00409994).Patient eligibility and treatment
Patients with a primary resectable rectal cancer, deﬁned as cT2–
3 without involvement of the circumferential resection margin
(CRM) as judged on MRI and cN0–1, for whom short course
pre-operative radiotherapy was advised in the Tumor Board meet-
ing, were eligible for inclusion in the trial. The most important
exclusion criterion was the concurrent use of CYP3A4 inhibiting
drugs.
An outline of the study is presented in Fig. 1. Radiotherapy
treatment consisted of 5 fractions of 5 Gy given within an overall
treatment time of 7 days. The treated volume consisted of the pri-
mary tumor, mesorectum, presacral area and internal iliac lymph
nodes. Patients were treated using a 4-ﬁeld 3D-conformal tech-
nique or a VMAT technique. During phase I patients were operatedpanel) and phase II (lower panel).
216 Rapamycin and radiotherapy in rectal cancerwithin 3 days after the last fraction of radiotherapy. In phase II
resection was performed preferably 7–8 weeks after completion
of radiotherapy, but a minimum interval of 6 weeks was required.
For cN+ patients, adjuvant chemotherapy was given according to
the regional protocol. In some patients 2 cycles of adjuvant
chemotherapy were given between the end of radiotherapy and
surgery.
Rapamycin treatment was started 1 week before the start of
radiotherapy. For phase I, three dose levels were deﬁned: 2 mg,
4 mg and 6 mg daily respectively. Cohorts of 3–6 patients were
treated. If no DLT occurred, then subsequent patients were treated
at the next dose level. In order to monitor rapamycin plasma levels,
blood samples were taken on day 4, 8 and 15. Trough levels aimed
at were 5–15 lg/l for dose level (DL) 1, 10–30 lg/l for DL2 and 15–
45 lg/l for DL3, to guarantee that plasma levels were comparable
between patients during radiotherapy. The desired trough levels
were based on the experience in kidney transplant patients. If
plasma levels were lower than expected on day 4, patients were
instructed to increase the rapamycin dose. Plasma levels were then
checked again on day 8 just before the start of radiotherapy. For
phase II, the recommended phase II dose (RP2D) resulting from
phase I was used. A schematic overview of the treatment is given
in Fig. 1.Patient evaluation
During phase I acute toxicity was scored after 1 week of rapa-
mycin single use, at the day of the last fraction of radiotherapy
and weekly thereafter until 4 weeks post-operatively. Toxicity
was graded according to the common toxicity criteria
(NCI-CTCAE v3.0). Dose limiting toxicity (DLT) was deﬁned as
grade 4 or 5 postoperative toxicity. Secondary endpoints for phase
I were incidence of other toxicity and activation status of mTOR
related and dependent molecules in the tumor. During phase II,
toxicity was evaluated at the same time points during treatment
and every 2 weeks after treatment until resection. Secondary end-
points for phase II were tumor response, incidence of acute toxicity
and changes in tumor metabolism as measured on PET scan.Table 1
Patient characteristics.
Characteristic Phase I (n = 13) Phase II (n = 31)
Sex
Male 11 (85) 21 (68)
Female 2 (15) 10 (32)
Age
Median 62 (49–82) 66 (44–82)
cT stage
T2 5 (38) 10 (32)
T3 8 (62) 21 (68)
cN stage
N0 4 (31) 21 (68)Treatment evaluation
During phase II an FDG-PET–CT scan was performed before start
of treatment, at day 8 after 1 week of rapamycin use only and on
day 14, directly after completion of radiotherapy. A fourth scan
was made around day 64. Changes in perfusion were measured
by means of a perfusion CT-scan (pCT), which was made with
the PET–CT scanner directly after the PET-scan. The volume for
perfusion measurement was located within the area of high
FDG-uptake, to ensure central location within the tumor. The
trans-endothelial volume transfer constant Ktrans was measured
at all different time points. Ktrans describes the transfer rate of con-
trast agent from the blood to the extravascular-extracellular space.
Technical details have been described previously [11]. PET-scans
were used to analyze changes in metabolic activity.N1 9 (69) 10 (32)
Type of surgery
LAR 10 (77) 24 (77)
APR 3 (23) 2 (7)
TEM 0 5 (16)
(y)pT stage
T0 0 1 (3)
T1 1 (8) 3 (10)
T2 6 (46) 17 (55)
T3 5 (38) 10 (32)
T4 1 (8) 0
(y)pN stage
N0 7 (54) 21 (68)
N1 6 (46) 10 (32)Statistical analysis
Differences in perfusion and changes in metabolic activity were
analyzed using the Wilcoxon signed rank test. Primary endpoint
for phase I was incidence of severe postoperative complications
(grade 4 or grade 5 toxicity). Primary endpoint for phase II was
tumor blood ﬂow (Ktrans) assessed by perfusion CT on day 14.
Secondary endpoints were incidence of acute toxicity, pathological
response and metabolic response. It was hypothesized that tumor
perfusion measured as Ktrans would decrease with 40% [12] with a
standard deviation of 26 [13]. A sample size of 44 patients wasrequired for a beta error of 5% and an alpha error of 10%. The drop-
out rate was estimated to be 10%, and therefore the inclusion of 47
patients was aimed for.Tissue correlative studies
In phase I extra tumor biopsies were taken after 1 week of rapa-
mycin monotherapy and after completion of radiotherapy at the
time of surgery. Tumor biopsies were stained immunohistochemi-
cally, for phospho-mTOR (Bioke #2976) and phospho-4E-BP1
(Bioke #9451), according to the manufacturer’s protocol. It was
hypothesized that the use of rapamycin, an mTOR inhibitor, would
result in a decrease of mTOR and 4E-BP1 phosphorylation. Sections
were scored by two individual pathologists. Cytoplasmatic, mem-
branous and nuclear staining of the tumor cells was scored as
strong (>90% tumor cell positivity), moderate–strong (60–90%
tumor cell positivity), moderate (40–60% tumor cell positivity)
weak–moderate (10–40% tumor cell positivity) and negative
(<10% tumor cell positivity).Results
Thirteen patients were entered in phase I of the study, between
November 2006 and March 2009. Three patients were treated in
DL1, 4 in DL2 and 6 in DL3. Patient characteristics are shown in
Table 1. In DL1 no dose adjustments were necessary at day 4, in
order to reach the planned plasma trough levels at the start of
radiotherapy. In DL2 2 patients needed a dose adjustment to
6 mg rapamycin daily. In DL3 a dose adjustment was needed in 4
patients. In 2 patients the daily dose of rapamycin was increased
to 10 mg and in 2 patients to 12 mg.
During the preoperative treatment with rapamycin only and
radiotherapy with rapamycin no toxicities greater than grade 2
were observed. The most reported mild side effects were headache,
diarrhea and stomatitis. In the postoperative phase, 2 patients suf-
fered from a grade 3 wound infection, one patient in DL1 and one
in DL3. Four patients experienced a grade 3 ileus, which persisted
for >1 week in 1 patient (1 patient in DL1, 2 patients in DL2 and 1
in DL3). Two patients developed a grade 3 leak (1 in DL1 and 1 in
DL2) and 1 patient was faced with a grade 4 leak (treated in DL3).
Table 2
Overview of toxicities in phase I.
Patient
no
Dose level
rapamycin
Dose
adjustment
Adjusted
dose
Toxicity Pgr 3
1 2 mg n gr 3 wound
infection
2 2 mg n gr 3 ileus
3 2 mg n gr 3 GI leak
4 4 mg y 6 mg
5 4 mg n gr 3 ileus
6 4 mg n gr 3 ileus
gr 3 GI leak
gr 3 anorexia
7 4 mg y 6 mg
8 6 mg y 10 mg
9 6 mg y 12 mg gr 3 ileus
gr 3
malabsorption
gr 3 wound
infection
10 6 mg n gr 3 colitis
gr 4 GI leak
gr 4 hemorrhage
11 6 mg n
12 6 mg y 10 mg
13 6 mg y 12 mg
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grade 3 colitis. In total 7 patients developed grade 3 or higher tox-
icities (some patients developed >1 toxicity). A complete overview
of all toxicities Pgrade 3 is given in Table 2.
Although only one case of DLT was observed and according to
the protocol DL3 could be declared the RP2D, based on the clinical
judgment of the investigators the percentage of postoperative
grade 3 toxicities was deemed unacceptable compared to theFig. 2. Immunohistochemical analysis of the phosphorylation status of mTOR (upper pa
(right panels) on tumor biopsies of the same patient.published toxicity proﬁle of 5  5 Gy without rapamycin. Because
wound infections and leakage may have been inﬂuenced by the
immunosuppressive, protein synthesis inhibiting and
anti-angiogenetic effects of rapamycin [14], it was decided in
accordance with the ethical committee to postpone the time of
surgery for phase II to 7–8 weeks after the completion of radiother-
apy. A daily dose of 6 mg rapamycin was declared RP2D.
Tumors were stained immunohistochemically for phosphoryla-
tion of mTOR and 4E-BP1 (Fig. 2). For the p-mTOR staining, results
were available for 7 patients. In 4 patients, no invasive tumor was
left in the biopsy material taken pre-treatment and in 2 patients
there were technical difﬁculties. In 1 patient p-mTOR was scored
as ‘strong’ before treatment, ‘moderate–strong’ in 4 patients, ‘mod-
erate’ in 1 patient and ‘weak–moderate’ in 1 patient. In 3 patients
no change in phosphorylation status of mTOR was observed, in 3
patients there was a slight increase in p-mTOR and in one patient
a decrease in p-mTOR was found. Phosphorylated 4E-BP1 data
were available for 8 patients. In 4 patients, no invasive tumor
was left in the biopsy material taken pre-treatment and in 1
patient there were technical difﬁculties. The pre-treatment score
was ‘strong’ in 5 patients and ‘moderate–strong’ in 3 patients. In
6 patients a slight decrease in p4E-BP1 status was found, while 1
patient showed a slight increase and in 1 patient a phosphorylation
status remained stable. No clear correlation between changes in
p-mTOR staining and p-4E-BP1 staining was observed.
In total, thirty-one patients were entered in phase II, between
April 2010 and April 2013. Inclusion was stopped because the pro-
portion of rectal cancer patients referred for short-course radio-
therapy decreased due to a change in the national guidelines and
because it became clear that the primary endpoint would not be
reached. Patient characteristics are shown in Table 1. All patients
received 6 mg rapamycin daily. In 18 patients a dose adjustmentnels) and 4E-BP1 (lower panels) before treatment (left panels) and after treatment
218 Rapamycin and radiotherapy in rectal cancerwas necessary on day 4, in order to reach the planned plasma
trough levels at the start of radiotherapy. Six patients were
switched to 8 mg rapamycin daily, 8 patients to 10 mg and 4
patients to 4 mg. The rapamycin plasma levels are depicted in
Fig. 3.
During the ﬁrst 2 weeks of treatment (rapamycin only and
radiotherapy combined with rapamycin) no toxicities worse than
grade 2 were reported. Two weeks after completion of radiother-
apy one patient reported grade 3 diarrhea, nausea and vomiting.
This was the only grade 3 or higher toxicity reported in the interval
between radiotherapy and surgery and it was judged to be related
to the chemotherapy that was started after completion of radio-
therapy. The most frequently reported toxicities
post-radiotherapy were proctitis (45% grade 1–2 on day 22 and
19% on day 36) and diarrhea (45% grade 1–2 on day 22 and 35%
on day 36). No severe postoperative complications have been
reported in phase II.
The results of the changes in PET-activity and tumor perfusion
are summarized in Table 3. Metabolic activity decreased signiﬁ-
cantly after 1 week of rapamycin only treatment (mean SUVmax
14.5 vs. 12.3 (p = .033)). No further signiﬁcant decrease was
observed at the last day of radiotherapy (mean SUVmax 12.3 vs.
11.8 (p = .113)). On day 64 a marked further decrease in
FDG-uptake was found (mean SUVmax 6.8 (p < .001)). Tumor vol-
ume measured on PET-scan decreased gradually over time, as well
after rapamycin treatment as after 5  5 Gy. Tumor perfusion, as
reﬂected by Ktrans, remained at a constant level during the entire
treatment. It was not possible to analyze any differences between
responders and non-responders because the proportion of patients
showing a ypT0/1 was too small.
In 29 patients sphincter saving surgery was initially performed:
a low anterior resection (LAR) in 24 patients and transanal endo-
scopic microsurgery (TEM) in 5 patients (Table 1). In the remaining
2 patients an abdominoperineal resection (APR) was chosen. Two
of the ﬁve patients who were initially treated by TEM were ﬁnally
diagnosed with a ypT3 tumor, which consequently led to a LAR
subsequently. One patient was diagnosed with a pCR in theDay 4 Day 8 Day 15
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Fig. 3. Rapamycin plasma trough levels on day 4, 8 (start of radiotherapy) and 15
(last day of radiotherapy). Plasma levels should be P15 lg/l.
Table 3
PET and perfusion parameters.
Day 0 Day 8
SUVmax 14.5 (5.2–27.9) 12.3 (4.2–21.0) p = .0331
PET volume 13.6 (2.10–30.2) 12.0 (3.1–27.9) p = .0191
Ktrans mean .55 (0.31–0.82) .54 (.30–.87) p = .921
1 Wilcoxon signed rank test, SUVmax as compared to the scan one timepoint earlier.resected specimen and 2 patients developed a local recurrence 5
resp. 12 months after TEM One of these 2 patients was salvaged
by chemoradiation followed by a pelvic exenteration and the sec-
ond patient underwent a salvage APR. Unfortunately this last
patient was recently diagnosed with a second local recurrence.
Median time between end of radiotherapy and surgery was
65 days (range 45–235).
Apart from the patient with a pathological complete response in
the TEM-specimen, in 3 patients the tumor was downsized to
ypT1N0, resulting in a major response in 13% of patients (4 out
of 31). Seventeen patients had a T2 tumor at the time of resection;
in 4 (24%) of them positive nodes were found in the resected spec-
imen. Of the 10 patients who still had a T3 tumor after neoadjuvant
treatment, 6 had positive nodes (60%). After a median follow-up of
39 months, 3 patients (7%) developed metastases. At the date of
last follow up 2 patients had died of their metastases.Discussion
This phase I/II trial used change in tumor perfusion as a surro-
gate endpoint in order to have a rapid endpoint of biological activ-
ity and to gain insights into a speciﬁc mechanism of action of
rapamycin in combination with radiotherapy. This novel approach
allows for a more rapid answer to speciﬁc research questions for a
biological modiﬁer, as compared to more classical endpoints such
as local control and overall survival. In contrast to the hypothesis,
no change in perfusion was seen, nor after rapamycin nor after
combined rapamycin and radiotherapy. The combination of radio-
therapy and rapamycin turned out to be safe, on the condition that
surgery was delayed to 8 weeks after the end of radiotherapy.
Although the formal criteria for DLT were not met in phase I of
this trial, the postoperative toxicity observed in phase I of the
study was quite remarkable and deemed clinically unacceptable.
Wound healing can be inﬂuenced by mTOR inhibitors by the inhi-
bition of angiogenesis and ﬁbroblast proliferation [14,15]. There is
some evidence from randomized trials using different immunosup-
pressive regimens in post-transplant patients that wound compli-
cations occur more often in patients using rapamycin as compared
to patients using other types of immunosuppressants, especially in
patients with high trough concentrations (15–20 ng/ml) [14,15]. In
our study, postoperative toxicities were observed at all dose levels.
In phase II, after the introduction of delayed surgery, no severe
postoperative toxicities were seen. Although the patient numbers
do not allow ﬁrm conclusions, we think it is thus advisable to keep
a gap between any neo-adjuvant treatment with mTOR inhibitors
and surgery.
The pCR rate observed in phase II of this trial was low compared
to other studies reporting on 5  5 Gy followed by delayed resec-
tion [8,9,16,17]. In this small patient group only 1 patient (3%)
developed a pCR. A possible explanation could be the proliferation
slowdown by inhibition of mTOR leading to cell cycle arrest [18]. A
slower proliferation may result in a slower mitotic cell death after
irradiation and thus a slower tumor response. Recently, a paper
reviewing the negative feedback loops that become activated as a
result of mTOR inhibition, has been published. Suppression of
these feedback loops leads to overactivation of upstream path-
ways, including PI3K, AKT and ERK. This may counteract theDay 15 Day 64
11.8 (3.8–28.2) p = .1131 6.8 (0–15.8) p < .0011
9.9 (1.0–25.3) p = .0351 6.0 (0–24.8) p < .0011
.51 (.26–.83) p = .261 .50 (.40–.60) p = .721
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sion about the usefulness of pCR as a surrogate endpoint.
Recently the endpoint of 2-year disease free survival had been
proposed [20].
Primary endpoint of the study was a decrease in tumor perfu-
sion as reﬂected by Ktrans. This endpoint was not met and actually
no change in Ktrans was found, neither after rapamycin run-in nor
after rapamycin and radiotherapy. A possible explanation could
be a mechanism that was observed in another study by our group
after the development of this trial. Ktrans values were measured in
23 patients treated with short-course radiotherapy only (5  5 Gy)
before and after SCRT [11]. A signiﬁcant increase in perfusion was
observed. However, in the present study Ktrans remained
unchanged during radiotherapy and the addition of rapamycin. It
could therefore be hypothesized that the increase in Ktrans that
was observed after 5x5 Gy without rapamycin was counterbal-
anced by the decrease in Ktrans expected to result from the
anti-angiogenic effects of rapamycin. Recently published data
using everolimus, another mTOR inhibitor, also did not observe a
change in tumor perfusion measured with DCE-MRI after everoli-
mus monotherapy [21]. The inﬂuence of rapamycin on tumor vas-
culature was studied in a rhabdomyosarcoma mouse model [5]. In
this model, a decrease in tumor microvasculature was found and
an increase in oxygenation was observed, but tumor vessel perme-
ability only minimally changed. This raises the question whether
perfusion imaging is the most suitable method to evaluate vascu-
lature changes caused by rapamycin. However, Willett et al. found
the same changes in microvessel density after the administration
of bevacizumab, a VEGF antibody, but they noted a clear decrease
in tumor perfusion on perfusion CT [12]. Ktrans describes the trans-
fer rate of contrast agent from the blood to the
extravascular-extracellular space and is related to microvascular
blood ﬂow, vessel wall permeability and vessel density. This means
that this constant is inﬂuenced by different aspects of tumor vascu-
lature. A pre-clinical study looked at the speciﬁc anti-angiogenic
mechanisms of an mTOR inhibitor (everolimus) as compared to a
VEGFR tyrosine kinase inhibitor [22]. They described that alter-
ations in tumor vascular biology were partly caused by comparable
mechanisms but differences in the vascular response were also
observed. In the mouse model of this study, Ktrans as measured with
DCE MRI remained constant during mTOR treatment, despite a
clear tumor response, but a clear decrease in Ktrans was seen after
treatment with a VEGFR inhibitor. Apparently, different ways of
anti-angiogenic treatment result in different types of vasculature
changes and this translates into different changes on imaging.
Furthermore, responses of tumor vasculature to mTOR inhibitors
can be quite heterogeneous possibly depending on differences in
the tumor microenvironment [23].
In contrast to the perfusion scans, a signiﬁcant decrease in
metabolic activity was seen on PET–CT. This observation is in line
with the ﬁndings of Ciunci et al. in their phase I trial with everoli-
mus and cetuximab [21]. Recently a quick and clear decrease in
FDG uptake was demonstrated under mTOR1/2 inhibition in a
mouse glioma model [24]. In a preclinical model of
cisplatin-resistant ovarian cancer, treatment with a dual
PI3K/mTOR inhibitor resulted in a signiﬁcant decrease of
FDG-uptake, which correlated with a decrease in proliferation
and inhibition of the PI3K/mTOR pathway [25]. In a mouse model
in which colon tumors are initiated by a dominant active PI3K, a
clear response was seen on PET-scan after treatment with rapamy-
cin, but not after placebo treatment [26]. Honer et al. used different
cell lines in a mouse model: cell lines that were in vitro character-
ized as sensitive to everolimus and cell lines that were insensitive.
The insensitive cell lines did show growth inhibition but no
changes in FDG metabolism were observed, while in the sensitive
tumor model a clear decrease of FDG-uptake was observed [27].The authors hypothesize that this may be explained by a different
mechanism of action, namely the anti-angiogenic action of evero-
limus, and that the change in FDG-metabolism is caused by other
mechanisms. In a study with patients with metastatic renal cell
cancer, a decrease in FDG-uptake was found after treatment with
everolimus [28]. This early metabolic change was correlated with
change in tumor burden.
The results of the immunostainings are difﬁcult to interpret.
The expected decrease of phosphorylation status of mTOR is not
clearly observed. The limited patient group makes it difﬁcult to
draw conclusion and does not allow to perform a reliable statistical
analysis.
In conclusion, rapamycin turned out to be safe in combination
with short-course hypofractionated radiotherapy in rectal cancer
treatment, but it is advisable to postpone surgical treatment until
8 weeks after combined treatment to avoid a possible increase in
postoperative complications. Although rapamycin is thought to
cause changes in tumor vasculature, this does not translate into
changes in Ktrans in vivo. Rapamycin has a biological inﬂuence on
rectal cancer as reﬂected by the changes in FDG-uptake. In this
patient cohort no clear increase in tumor response was observed
after combined radiotherapy and rapamycin.
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